The developers of this reporting guideline have found evidence that clinical trials of Chinese herbal medicine formulae frequently fail to report on adverse events. They propose to create a checklist to help researchers report more explicitly methods and procedures for observing adverse reactions as well as provide more thorough and in-depth information on the population, severity, and medication conditions of adverse reactions in such trials, toxicological tests and safety evaluations.
Developers plan to review the literature to identify potential items for the checklist, run Delphi surveys and a consensus meeting to finalise wording, pilot test and finalise and publish the reporting guideline and an explanation and elaboration documents in open-access journals in 2027. They also plan to submit the work to conferences. The project leaders have applied for funding by the Chinese Medicine Development Fund Hong Kong.
Registered: 16 January 2024
Last updated:
Contact: Xuan Zhang Email: [email protected]